Quest Diagnostics

VentiRx Pharmaceuticals

VentiRx Pharmaceuticals receives Fast Track designation for Motolimod (VTX-2337)

Friday, September 5, 2014 10:59 AM

The FDA has granted Fast Track designation to VentiRx Pharmaceuticals’ motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. Motolimid is a novel TLR8 immunotherapy currently being evaluated in two randomized, placebo-controlled, phase II trials.

More... »


VentiRx Pharmaceuticals appoints James Kyle Bryan as CMO

Thursday, April 25, 2013 08:00 AM

VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company focused on novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases, has appointed James Kyle Bryan, M.D., as chief medical officer. 

More... »


VentiRx, Celgene collaborate on novel TLR8 agonist VTX-2337 for cancer

Thursday, October 4, 2012 11:03 AM

VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company focused on novel Toll-like receptor 8 (TLR8) agonists and antagonists, has formed an exclusive, world-wide collaboration with Celgene, an integrated global biopharmaceutical company, for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs